AMAG Pharmaceuticals: Enough Irons In The Fire?
Demand for AMAG’s newly launched Feraheme has been robust but a changing reimbursement climate, especially in the dialysis market, complicates the product’s pricing strategy, and puts increased pressure on management to diversify via dealmaking.
You may also be interested in...
Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market
Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.
A New Course For AMAG: Expanding Feraheme And Moving Beyond Iron
AMAG is looking to build out its portfolio by in-licensing or acquiring new commercial products that complement its I.V. iron product Feraheme. The company is in negotiations for multiple assets, while at the same time preparing to launch Feraheme into a broader patient population.
AMAG’s Feraheme Expansion Strategy Delayed For Now
FDA has extended by three months its review of a sNDA for the I.V. iron product that would expand the drug’s use into a far broader patient population.